BBIO BridgeBio Pharma

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio.

Dr. Wicklund will provide an overview of limb-girdle muscular dystrophy (LGMD), specifically focusing on the disease burden, standard of care and unmet needs for those with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related). He serves as director for the UT Health San Antonio MDA Multidisciplinary Care Center and is a member of the Limb-girdle Muscular Dystrophy Clinical Research Network and the Neuromuscular Study Group. Dr. Wicklund has participated in over 35 multi-center clinical trials in the areas of muscular dystrophy, ALS, and myasthenia gravis and has over 200 published articles, chapters and abstracts.

In addition to Dr. Wicklund, executive members of the LGMD2I/R9 program will review the progress of BBP-418 to date and discuss expectations for the Phase 3 interim analysis results expected in the second half of 2025.

To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on , , and .

BridgeBio Media Contact:

Bubba Murarka, Executive Vice President

  

(650)-789-8220

BridgeBio Investor Contact:

Chinmay Shukla, VP Strategic Finance



EN
26/06/2025

Underlying

BBIOBridgeBio Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BridgeBio Pharma

 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results ...

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscriptAttruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the grea...

February 24, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Participate in March Investor Conferences

BridgeBio to Participate in March Investor Conferences PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences: TD Cowen 46th Annual Healthcare Conference, Boston, MA: Fireside Chat on Monday, March 2 at 3:50 pm ESTLeerink Partners Global Healthcare Conference, Miami, FL: Fireside Chat on Tuesday, March 10 at 1:00 pm EDTBar...

February 23, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on February 12, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 34 new employees in restricted stock units for an aggregate of 76,701 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock u...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Result...

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. BridgeBio will host a conference call to discuss the financial results and program updates a...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratin...

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch